Industry News
Pharmaceutical Industry News
Novartis has filed suit against…
Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.
With plans to pay $2.1 billion to…
With plans to pay $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more importantly, the deal lays the
Novavax will remain headquartered…
Novavax will remain headquartered at another location nearby in Maryland as AstraZeneca takes over its former corporate headquarters in Gaithersburg.
The White House is preparing a…
The White House is preparing a probe to explore whether any U.S. trade partners aren’t paying enough for medicines, the Financial Times reported Wednesday. Unlike the administration’s previous investigation into the national security implications of
How Testosterone Is Giving Middle-Aged Women the Best Sex of Their Lives
There is no F.D.A.-approved testosterone product for women. Insurance won’t cover it. Many doctors won’t prescribe it. It’s become a cultural phenomenon.
The FDA’s recent barrage of…
The FDA’s recent barrage of letters calling out alleged violations of federal pharma marketing rules poses a challenge to drugmakers. Ad agency Real Chemistry is applying AI to the task.
With the settlement, Celltrion can…
With the settlement, Celltrion can launch its recently approved Eylea biosimilar Eydenzelt on Dec. 31, 2026, in the same indications that Eylea treats.
Healthcare and pharma companies…
Healthcare and pharma companies sometimes engage with Hispanic audiences enthusiastically—but also often neglect the growing demographic.
Axial Therapeutics has stepped…
Axial Therapeutics has stepped back into the spotlight, emerging after almost two years of silence with a new name, focus and financing.
Novo said Tuesday that it will…
Novo said Tuesday that it will host an extraordinary general meeting on Nov. 14 to elect new members to its board following an impasse in leadership discussions involving the Danish drugmaker’s chief shareholder, the Novo
The company publicly responded to…
The company publicly responded to a Citizen Petition that urges the FDA to add warnings about the use of the over-the-counter pain med during pregnancy.
After clearing Novo Nordisk’s…
After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular events (MACE), the FDA has followed suit with a MACE expansion for its semaglutide pill Rybelsus.
Private equity firm Curewell…
Private equity firm Curewell Capital is aiming to close the gap in U.S. API production with a majority investment in specialty CDMO Wilmington PharmaTech.
ACG, a supplier for solid dose…
ACG, a supplier for solid dose drug manufacturers, is pumping $200 million into what will be the India-based company’s first empty-capsule production facility in the U.S.
As Big Pharmas increasingly roll…
As Big Pharmas increasingly roll out platforms for direct-to-consumer drug sales, most offering steep discounts on popular medications, many patients are open to using the new services, a recent survey found.
Merck has just registered the 15th…
Merck has just registered the 15th global phase 3 trial for its TROP2 antibody-drug conjugate, sac-TMT, just as its Chinese partner Kelun-Biotech reported two sets of strong phase 3 results in patients with lung cancer
Though spending on pharmaceutical…
Though spending on pharmaceutical TV ads picked up last month following a summer slump, the third quarter’s overall total still paled in comparison to the preceding periods this year.
Early Monday, Roche announced that…
Early Monday, Roche announced that the FDA cleared its 12-year-old oncology drug Gazyva to treat adults with active lupus nephritis who are taking standard therapy. The move into lupus nephritis comes late into the life
The investment is part of the New…
The investment is part of the New Jersey company’s plan to spend more than $70 billion on manufacturing, R&D and capital projects in the U.S. starting this year.
Theravance Biopharma is stepping…
Theravance Biopharma is stepping up efforts to educate physicians about neurogenic orthostatic hypotension associated with multiple system atrophy, launching its “Power in the Periphery” campaign in the run-up to publication of phase 3 data in